Clinical Trial Update: AHN-12 Biodistribution in Advanced Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial of the investigational agent AHN-12 focusing on biodistribution in advanced leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AHN-12

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: TERMINATED